Brett Arbon
Nurse Practitioner · Pleasant View, UTNPI 1578527909
Payments from drug & device makers
Across 209 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$737
- Pfizer$301
- GSK$261
- Astellas Pharma US Inc$201
- AstraZeneca$172
- Lilly USA, LLC$119
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,072100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 68 | $737 |
| Pfizer | 17 | $301 |
| GSK | 17 | $261 |
| Astellas Pharma US Inc | 11 | $201 |
| AstraZeneca | 7 | $172 |
| Lilly USA, LLC | 8 | $119 |
| Dynavax Technologies Corporation | 8 | $117 |
| Organon | 11 | $95 |
| Ironshore Pharmaceuticals Inc. | 5 | $79 |
| Baxter Healthcare | 2 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Amarin Pharma, Inc. | 5 | $68 |
| Amgen(2 entities) | 4 | $67 |
| Dexcom, Inc. | 3 | $62 |
| Johnson & Johnson | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Novo Nordisk | 3 | $47 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Abbott | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Merck | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Boston Scientific | 1 | $32 |
| Axsome Therapeutics, Inc. | 2 | $30 |
| Sanofi Pasteur Inc. | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 2 | $27 |
| Corium, LLC | 1 | $24 |
| Sanofi | 1 | $22 |
| Cranial Technologies, Inc | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| BD | 1 | $18 |
| Corcept Therapeutics | 1 | $17 |
| Treace Medical Concepts, Inc. | 1 | $15 |
| Sobi, Inc | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Genentech USA, Inc. | 2 | $14 |
| Biogen | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$3,072 in reported general payments places this provider in the 90th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 29 | $34,272 |
| EliquisApixaban | 15 | $26,567 |
| JanuviaSitagliptin Phosphate | 13 | $21,538 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $14,875 |
| XareltoRivaroxaban | 14 | $11,923 |
| JardianceEmpagliflozin | 11 | $9,732 |
| LinzessLinaclotide | 11 | $6,748 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $6,495 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 17 | $2,945 |
| Omeprazole | 93 | $1,817 |
| Triazolam | 13 | $1,598 |
| Levothyroxine Sodium | 140 | $1,583 |
| Atorvastatin Calcium | 152 | $1,540 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,334 |
| Tamsulosin Hcl | 49 | $950 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $47 | $34,27229 claims |
| PfizerEliquis | $301 | $26,56715 claims |
| MerckJanuvia | $35 | $21,53813 claims |
| GSKTrelegy Ellipta, Shingrix | $261 | $17,82032 claims |
| Johnson & JohnsonXarelto | $49 | $11,92314 claims |
| AbbVieLinzess | $737 | $6,74811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Pleasant View
- David GambleAmerican Fork$836K
- Julia BattenSalt Lake City$223K
- Stacie EganOgden$170K
- Traci AndreasonLehi$161K
- Geoffrey OsmondDraper$62K
- Trenton GraySouth Salt Lake$40K
- Kelsey FurrWest Jordan$21K
- Merin KinikiniSalt Lake City$19K
- Phillip BowmanSalt Lake City$18K
- Lynn LarsenOgden$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.